Palatin Announces Positive End-of-Phase 2 Meeting with FDA on PL9643 for the Treatment of Dry Eye Disease prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Nasal spray improves signs, symptoms of dry eye disease Source:
Raizman M, et al. ONSET-2 phase 3 study of OC-01 nasal spray for the treatment of dry eye disease. Presented at: Association for Research in Vision and Ophthalmology annual meeting; May 1-7, 2021 (virtual meeting). Disclosures:
Raizman reports he is a consultant for Oyster Point.
ADD TOPIC TO EMAIL ALERTS
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
Subscribe
ADDED TO EMAIL ALERTS
You ve successfully added to your alerts. You will receive an email when new content is published.
Operator
Good evening, and welcome to Oyster Point Pharma s first-quarter 2021 earnings conference call. My name is Sarah, and I will be your operator today. After the company s formal remarks, there will be a question-and-answer session. At this time, I would like to turn the call over to Mr.
Daniel Lochner, Oyster Point Pharma s chief financial officer. Please go ahead.
Dan Lochner
Chief Financial Officer
Good evening, everyone, and welcome to the Oyster Point Pharma first-quarter earnings conference call for the three months ending March 31, 2021. This issued a press release containing our first-quarter financial results and recent business highlights. In addition, our earnings press release and our Form 10-Q that was filed with the SEC after the close of the market today are available on our website under the investor and news section at www.oysterpointrx.com. Joining us on our call today are Dr.
Home / Top News / Oyster Point Pharma Announces Clinical Data Presentation of OC-01 (varenicline) Nasal Spray for Dry Eye Disease at the Association for Research in Vision and Ophthalmology 2021 Virtual Annual Meeting
Oyster Point Pharma Announces Clinical Data Presentation of OC-01 (varenicline) Nasal Spray for Dry Eye Disease at the Association for Research in Vision and Ophthalmology 2021 Virtual Annual Meeting
PRINCETON, N.J., May 01, 2021 (GLOBE NEWSWIRE) Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies to treat ocular surface diseases, announced today the presentation of data analyses from its Phase 3 ONSET-2 clinical trial evaluating OC-01 (varenicline) nasal spray for the treatment of signs and symptoms of dry eye disease at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Virtual Annual Meeting, being held on May 1-5.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Oyster Point Pharma Announces Clinical Data Presentation of OC-01 (varenicline) Nasal Spray for .
Oyster Point Pharma, Inc.May 1, 2021 GMT
PRINCETON, N.J., May 01, 2021 (GLOBE NEWSWIRE) Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies to treat ocular surface diseases, announced today the presentation of data analyses from its Phase 3 ONSET-2 clinical trial evaluating OC-01 (varenicline) nasal spray for the treatment of signs and symptoms of dry eye disease at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Virtual Annual Meeting, being held on May 1-5.